2140. Biological Features of Response to VE303, a Defined Bacterial Consortium, in Patients with Clostridioides difficile Infection (CDI): Results from the Phase 2 CONSORTIUM Study

BACKGROUND: Fecal transplant and other donor-derived treatments promote a gut environment resistant to CDI, but these treatments have inherently variable quality attributes, are difficult to scale, and can transfer harmful pathogens. VE303 is a rationally defined consortium of 8 purified, clonal str...

Descripción completa

Detalles Bibliográficos
Autores principales: Menon, Rajita, Crossette, Emily, Bhattarai, Shakti, Bucci, Vanni, Prince, Amanda L, Faith, Jeremiah, Olle, Bernat, Silber, Jeffrey L, Norman, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678313/
http://dx.doi.org/10.1093/ofid/ofad500.1763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678313/
http://dx.doi.org/10.1093/ofid/ofad500.1763

Ejemplares similares